文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

慢病毒载体的临床应用

Clinical use of lentiviral vectors.
PubMed 文献 · Leukemia · 2018-03-22

综述慢病毒载体的发展、临床应用、大规模生产及长期随访。第三代自失活慢病毒载体已用于多项临床试验,将基因导入造血干细胞以纠正原发性免疫缺陷和血红蛋白病,也用于导入CAR或克隆T细胞受体至成熟T细胞以产生抗肿瘤免疫。用慢病毒载体工程化的CAR T细胞疗法在B细胞恶性肿瘤中取得显著临床成功,促成首个使用慢病毒载体的基因工程细胞疗法获监管批准。

要点

  • 第三代自失活慢病毒载体已用于多项临床试验,将基因导入造血干细胞以纠正原发性免疫缺陷和血红蛋白病。
  • 慢病毒载体也用于将CAR或克隆T细胞受体导入成熟T细胞以产生抗肿瘤免疫。
  • 用慢病毒载体工程化的CAR T细胞疗法在B细胞恶性肿瘤中取得显著临床成功,促成首个此类疗法获监管批准。

核心结论

  • 慢病毒载体在原发性免疫缺陷、血红蛋白病和癌症的基因治疗中已有临床应用,用其工程化的CAR T细胞疗法在B细胞恶性肿瘤中取得显著临床成功并促成首个监管批准。

研究设计与样本

  • 综述,讨论慢病毒载体发展、作为原发性免疫缺陷和癌症治疗的应用、大规模生产及基因治疗产品的长期随访。

主要发现

  • 第三代自失活慢病毒载体已用于多项临床试验,将基因导入造血干细胞以纠正原发性免疫缺陷和血红蛋白病。
  • 慢病毒载体已用于将基因导入成熟T细胞,通过递送嵌合抗原受体(CAR)或克隆T细胞受体产生抗肿瘤免疫。
  • 用慢病毒载体工程化的CAR T细胞疗法在B细胞恶性肿瘤患者中取得显著临床成功,促成首个使用慢病毒载体的基因工程细胞疗法获监管批准。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018. PMID: 29654266. doi:10.1038/s41375-018-0106-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。